Supriya Lifescience Ltd. on Saturday, July 4, said the Special Investigation and Intelligence branch of the Customs Department has initiated probe against its general manager, sales and marketing officer Sreekant Sreedharan. The company said the proceedings were initiated against Sreedharan under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985 for a procedural lapse for a single export transaction of identified product for which the officer is under judicial detention.Supriya Life said the proceedings are not expected to have any material impact on its operations, financial position or governance. It said it is evaluating the implications of the proceedings and is obtaining appropriate legal advice.Rubicon ResearchRubicon Research informed the exchanges that the United States Food and Drug Administration (US FDA) had conducted an unannounced inspection of the company’s manufacturing facility at Pithampur, Madhya Pradesh, from June 29 to July 3, and issued Form 483 to the company with two observations.The board of Bliss GVS Pharma has appointed Rahul Adakmol as the Chief Executive Officer (CEO) of the company, effective July 15, as Narsimha Shibroor Kamath has stepped down as CEO, effective July 14, while continuing to serve as the Managing Director of the companyFortis HealthcareFortis Healthcare informed the exchanges that it has signed an Operations and Management (O&M) agreement with Dion Group for a 300-bed greenfield multi-specialty hospital to be developed at Dion Riverside Township, Trishulia, Cuttack, Odisha.Fermenta BiotechFermenta Biotech has received approval from Food Safety and Standards Authority of India (FSSAI) for its product Vitamin D3 (Cholecalciferol) - Plant Source. The product - VITADEE Green® - developed and manufactured in India, supports the Make in India vision and strengthens India’s self-reliance in nutrition solutions.Published on July 6, 2026